2 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 2 |
Follow fosaprepitant: new trials by email Literature Review of fosaprepitant trials Research Report on fosaprepitant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients Ondansetron, Dexamethasone, Neurokinin-1 Receptor Antagonist (NK1-RA) - Gynecologic Cancer | Phase 3 | Terminated | University of Michigan Rogel Cancer Center | 62 | 2020-12-28 | 2025-06-18 |
| Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) Fosaprepitant, Placebo for fosaprepitant, Ondansetron - Chemotherapy-induced Nausea and Vomiting | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 75 | 2015-09-14 | 2019-03-15 |
Vomiting (1)
Merck Sharp & Dohme LLC (1) · University of Michigan Rogel Cancer Center (1)
United States (1)
Aimee Rolston (1)
2014 (1)